Financial Performance - The company's operating revenue for Q3 2023 reached ¥451,759,202.77, representing a year-on-year increase of 31.38%[6] - Net profit attributable to shareholders for Q3 2023 was ¥47,259,179.24, reflecting a significant increase of 51.68% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥48,384,333.38, up by 41.17% year-on-year[6] - Basic earnings per share for Q3 2023 were ¥0.28, up by 55.56% compared to the same period last year[10] - The net profit attributable to shareholders for the year-to-date period increased by 22.91% compared to the same period last year[12] - Net profit for the third quarter of 2023 was ¥94,938,760.33, up from ¥65,367,688.01 in the same quarter of 2022, reflecting a growth of approximately 45.4%[36] - The net profit attributable to shareholders of the parent company for the third quarter was ¥84,064,585.99, compared to ¥68,394,595.45 in the same quarter of 2022, reflecting an increase of approximately 22.9%[36] - The total comprehensive income attributable to the parent company reached ¥86,028,250.37, compared to ¥71,970,830.44 in the previous year, reflecting an increase of approximately 19.5%[39] - Basic and diluted earnings per share both increased to ¥0.50 from ¥0.40, marking a 25% growth year-over-year[39] Assets and Liabilities - The total assets as of the end of Q3 2023 amounted to ¥2,301,663,558.17, an increase of 4.16% from the end of the previous year[10] - The total assets as of the end of the reporting period were ¥2,301,663,558.17, compared to ¥2,209,724,972.77 at the end of the previous year, showing an increase of about 4.1%[30] - Total liabilities increased to ¥559,181,329.47 from ¥527,934,808.32, marking a rise of approximately 5.9%[30] - The equity attributable to shareholders of the parent company reached ¥1,721,057,722.32, up from ¥1,675,556,748.68, indicating an increase of about 2.7%[30] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥34,283,548.58, down by 65.38% compared to the previous year[10] - Cash inflow from operating activities totaled ¥976,228,103.10, up from ¥901,980,839.21, indicating a rise of about 8.2%[42] - The net cash flow from operating activities was ¥34,283,548.58, a decrease from ¥99,030,532.23, showing a decline of approximately 65.4%[42] - Cash inflow from investment activities amounted to ¥1,380,358,586.75, compared to ¥1,081,464,632.91, representing an increase of around 27.6%[42] - The net cash flow from investment activities was ¥126,864,704.63, a significant recovery from a negative cash flow of -¥615,586,129.26 in the previous year[42] - The company reported a net increase in cash and cash equivalents of ¥146,332,312.30, contrasting with a decrease of -¥572,651,999.32 in the prior year[42] - Total cash and cash equivalents at the end of the period stood at ¥866,918,251.56, up from ¥580,619,199.10, reflecting an increase of approximately 49.3%[42] Research and Development - The company's R&D investment totaled ¥30,415,977.66 in Q3 2023, accounting for 6.73% of operating revenue, a decrease of 2.34 percentage points year-on-year[10] - Research and development expenses for the third quarter of 2023 amounted to ¥68,195,871.59, slightly down from ¥69,860,306.50 in the previous year[33] Shareholder Information - The company reported a total of 7,787 common shareholders at the end of the reporting period[14] Strategic Focus and Future Outlook - The company has not disclosed any significant new product developments or technological advancements during this reporting period[20] - There are no indications of market expansion or mergers and acquisitions in the current report[20] - The company has not provided specific future guidance or performance outlook for the upcoming quarters[20] - The report does not mention any significant changes in shareholder structure or related party transactions[20] Operating Costs - Total operating revenue for the first three quarters of 2023 reached ¥986,914,134.12, an increase from ¥836,731,606.49 in the same period of 2022, representing a growth of approximately 17.9%[30] - Total operating costs for the first three quarters of 2023 were ¥873,480,654.54, compared to ¥779,995,200.30 in 2022, indicating an increase of about 12.0%[30] Other Financial Metrics - The weighted average return on equity for Q3 2023 was 2.72%, an increase of 0.88 percentage points year-on-year[10] - The company's long-term equity investments were reported at ¥4,314,100.90, a slight decrease from ¥4,371,655.95 at the end of 2022, showing a decline of approximately 1.3%[25] - The total current assets decreased slightly to ¥1,776,318,126.77 from ¥1,794,875,195.52, a decline of about 1.0%[25] - The company's accounts receivable increased to ¥395,853,210.34 from ¥333,297,094.96, reflecting a growth of about 18.7% year-over-year[25] - Inventory levels rose to ¥165,306,646.59, compared to ¥148,810,966.21 at the end of 2022, indicating an increase of approximately 11.0%[25] - The company's deferred income tax liabilities were reported at ¥6,658,707.03, an increase from ¥5,112,008.42 in the previous year[30] - The total assets held for sale were not reported, indicating a potential area for future strategic focus[25] - The company did not report any net profit from the merged entity prior to the merger, consistent with the previous year[39] - The company is not applying new accounting standards or interpretations that would affect the financial statements for the current year[44]

证券代码：688687 证券简称：凯因科技 公告编号：2024-056 北京凯因科技股份有限公司 第六届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京凯因科技股份有限公司（以下简称"公司"）第六届董事会第五次会议 于2024年12月19日在公司会议室以现场结合通讯表决方式召开，根据《公司章程》 的相关规定，因本次会议为紧急会议，经全体董事一致同意豁免会议通知期限要 求，于2024年12月19日以口头方式通知全体董事、监事、高级管理人员召开本次 会议。会议应出席董事7名，实际出席董事7名。会议由董事长周德胜先生主持。 公司监事、高级管理人员列席了本次会议。会议的召集、召开程序符合《公司法》 和《公司章程》的相关规定。 二、董事会会议审议情况 会议以投票表决方式审议并通过了如下决议： （一）审议通过了《关于公司前期会计差错更正及财务报告、前期公告补充 披露的议案》 公司本次差错更正及追溯调整符合《企业会计准则第28号——会计政策、会 计估计变更和差错更正》《公开发行证券的 ...

Group 1: Company Overview - Beijing Kain Technology Co., Ltd. held its Q3 2024 earnings briefing on December 6, 2024 [2][3] - The meeting aimed to enhance communication with investors and provide a comprehensive understanding of the company's performance [6] Group 2: Shareholder Information - As of November 30, 2024, the number of shareholders reached 7,874 [6] - The company emphasizes the importance of shareholder engagement and feedback [6] Group 3: Financial Performance - The company reported a cumulative revenue of 1.011 billion yuan for the first three quarters of 2024 [6] - Kain Technology is committed to value management and believes that strong operational performance is the foundation for enhancing market value [6][8] Group 4: Investor Relations - The company actively engages in cash dividends and share buybacks to reward investors [8] - Kain Technology plans to strengthen communication with investors to continuously improve its market value [8] Group 5: Product Development - The application for additional indications for the product "Pai Yisheng" has been approved by the National Medical Products Administration and is expected to be launched soon [8]

证券代码：688687 证券简称：凯因科技 公告编号：2024-054 北京凯因科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京凯因科技股份有限公司（以下简称"公司"）已于 2024 年 10 月 22 日发 布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 年 第三季度经营成果、财务状况，公司计划于 2024 年 12 月 06 日下午 15:00-16:00 举行 2024 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2024年第三季度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 会议召开时间：2024 年 12 月 06 日(星期五)下午 15:00-16:00。 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance [2][12]. Core Views - The company's profit exceeded expectations, with significant improvements in marketing efficiency. The sales revenue for the first three quarters of 2024 reached 1.011 billion yuan, a year-on-year increase of 0.82%, while the net profit attributable to shareholders was 108 million yuan, up 19.74% year-on-year [1]. - In Q3 2024, the company achieved sales revenue of 414 million yuan, a decrease of 4.51% year-on-year, but the net profit attributable to shareholders increased by 26.53% year-on-year, primarily due to a significant reduction in sales expenses [1]. - The company plans to acquire an additional 5% stake in its subsidiary, increasing its ownership from 76% to 81% [1]. Financial Performance - For the first three quarters of 2024, the company reported a sales expense ratio of 48.76%, down 9.08 percentage points year-on-year, with absolute sales expenses of 493 million yuan, a decrease of 15% [1]. - The R&D expense ratio was 10.29%, up 3.49 percentage points year-on-year, with absolute R&D expenses of 104 million yuan, an increase of 52.54% [1]. - The management expense ratio was 8.59%, up 1.57 percentage points year-on-year, with absolute management expenses of 86.79 million yuan, an increase of 23.42% [1]. - The company’s gross profit margin was 81.94%, a decrease of 1.39 percentage points year-on-year [1]. Earnings Forecast and Valuation - The company’s innovative drug for hepatitis C, Kai Li Wei, has expanded its reimbursement indications, which is expected to enhance market share. The existing product Jin Shu Xi is projected to reach sales of over 1 billion yuan [1]. - The forecast for net profit attributable to shareholders for 2024-2026 is 140 million yuan, 183 million yuan, and 245 million yuan, with year-on-year growth rates of 20.4%, 30.8%, and 33.4% respectively [2][1]. - The corresponding price-to-earnings ratios are projected to be 35X, 26X, and 20X for the years 2024, 2025, and 2026 [1].

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company has shown an improvement in profitability, with a revenue of 1.01 billion yuan in the first three quarters of 2024, reflecting a year-on-year increase of 0.82%. The net profit attributable to shareholders reached 108 million yuan, up 19.74% year-on-year [2][4] - Revenue showed a quarter-on-quarter improvement, with Q3 revenue at 414 million yuan, a decrease of 4.51% year-on-year but an increase of 7.85% quarter-on-quarter. This improvement is attributed to the execution of procurement policies in over 90% of provinces for a key product and the contribution from a newly approved drug [2][4] - The company is advancing its innovative drug development, with a new indication for a key product recently accepted for review by the National Medical Products Administration, indicating significant market potential [2][4] Financial Summary - For 2024 to 2026, the company is projected to achieve revenues of 1.566 billion yuan, 1.858 billion yuan, and 2.245 billion yuan, with year-on-year growth rates of 10.9%, 18.7%, and 20.8% respectively. The net profit attributable to shareholders is expected to be 143 million yuan, 185 million yuan, and 244 million yuan, with growth rates of 22.7%, 29.4%, and 31.6% respectively [2][4] - The company's earnings per share (EPS) is projected to increase from 0.84 yuan in 2024 to 1.42 yuan in 2026, reflecting a positive growth trajectory [4][5]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price range of 31.50 to 36.75 CNY per share based on a projected PE ratio of 30-35 times for 2025 [6][9]. Core Insights - The company has shown a significant decrease in sales expense ratio, which has driven rapid profit growth. For the first three quarters of 2024, the company achieved operating revenue of 1.011 billion CNY, a year-on-year increase of 0.82%, and a net profit attributable to shareholders of 108 million CNY, up 19.74% year-on-year [4]. - The company’s innovative biological product, Paiyisheng, has received acceptance for its listing application for treating chronic hepatitis B, which could create a second growth curve for the company. The potential market for chronic hepatitis B treatment in China is substantial, with approximately 20-30 million patients [5]. Financial Performance Summary - For 2024, the company is expected to achieve a net profit of 142 million CNY, with earnings per share (EPS) projected at 0.83 CNY. The compound annual growth rate (CAGR) for profit over the next three years is anticipated to exceed 20% [5]. - The company’s operating revenue is forecasted to grow from 11.60 billion CNY in 2022 to 21.17 billion CNY by 2026, with net profit increasing from 830 million CNY to 2.32 billion CNY over the same period [7]. - The gross profit margin for Q3 2024 was reported at 80.53%, with a net profit margin of 17.11%, reflecting a year-on-year increase of 3.41 percentage points [4]. Market Comparison - As of October 22, 2024, the company’s market capitalization stands at approximately 4.954 billion CNY, with a current price of 28.97 CNY per share, within a 52-week price range of 19.44 to 37.62 CNY [1].

证券代码：688687 证券简称：凯因科技 公告编号：2024-050 北京凯因科技股份有限公司 第六届董事会第四次会议决议公告 本议案已经公司第六届董事会审计委员会第四次会议审议通过。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 具体内容详见公司登载于上海证券交易所网站（www.sse.com.cn）上的《北 京凯因科技股份有限公司2024年第三季度报告》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京凯因科技股份有限公司（以下简称"公司"）第六届董事会第四次会议 于2024年10月21日在公司会议室以现场结合通讯表决方式召开，会议通知于2024 年10月14日以电子邮件、电话方式送达。会议应出席董事7名，实际出席董事7名。 会议由董事长周德胜先生主持。公司监事、高级管理人员列席了本次会议。会议 的召集、召开程序符合《公司法》和《公司章程》的相关规定。 二、董事会会议审议情况 会议以投票表决方式审议并通过了如下决议： （一）审议通过了《关于公司 2024 年第三季度报告的议案》 ...

证券代码：688687 证券简称：凯因科技 公告编号：2024-053 北京凯因科技股份有限公司 关于增加银行综合授信额度的公告 为满足生产经营和业务发展的需要，在确保运作规范和风险可控的前提下， 公司于 2024 年 10 月 21 日召开第六届董事会第四次会议，审议通过了《关于公 司增加银行综合授信额度的议案》，同意公司向兴业银行、建设银行、招商银行、 民生银行等银行申请增加授信额度，增加后综合授信额度总计不超过人民币 10 亿元，上述授信额度授信形式包括但不限于流动资金贷款、非流动资金贷款、承 兑汇票、保理、保函、开立信用证、票据贴现等授信业务。授信额度有效期自本 次董事会审议通过之日起至 2024 年年度董事会审议年度授信额度事项之日止。 在授信期限内，授信额度可循环使用。具体授信额度、要素最终以银行实际审批 为准。公司将视实际需求在不超过上述授信额度范围内办理具体贷款相关事宜， 1 具体金额以实际发生为准。 为提高工作效率，统一授权公司管理层办理上述授信额度申请事宜，并签署 合同、协议、凭证等相关文件。上述授信总额度内的单笔融资不再上报董事会进 行审议表决，由董事长确定并执行。 特此公告。 北京凯因 ...

根据《上海证券交易所科创板股票上市规则》等法律法规和《公司章程》的 相关规定，因汤键先生为公司高级管理人员，本次交易构成关联交易，但不构成 《上市公司重大资产重组办法》规定的重大资产重组，不存在重大法律障碍。 截至本公告披露日，在过去12个月内，除本次交易所涉事项外，公司与汤键 先生未发生其他关联交易。本次关联交易属于董事会审批权限范围内，无需提交 股东大会审议。 二、关联方基本情况 （一）关联关系说明 海通证券股份有限公司关于北京凯因科技股份有限公司 收购控股子公司少数股东股权暨关联交易的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为北京 凯因科技股份有限公司（以下简称"凯因科技"或"公司"）首次公开发行股票 并在科创板上市持续督导保荐机构，根据《证券法》《上市公司证券发行注册管 理办法》《证券发行上市保荐业务管理办法》等有关规定，对凯因科技履行持续 督导义务，根据《上海证券交易所上市公司自律监管指引第5号——交易与关联 交易》的规定，在持续督导期内，对公司拟收购控股子公司少数股东股权暨关联 交易事项进行了核查，具体情况如下： 一、本次关联交易概述 基于公司战略和业务发展需要，公司 ...